Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer

Journal of Nuclear Medicine

Volumn 55, Issue 1, 2014, Pages 107-114

  Bandekar, Amey ^a   Zhu, Charles ^a   Jindal, Rohit ^a   Bruchertseifer, Frank ^b   Morgenstern, Alfred ^b   Sofou, Stavroula ^a  

^a RUTGERS UNIVERSITY   (United States)

^b JOINT RESEARCH CENTRE   (Italy)

Author keywords

Anti PSMA liposomes; Antivascular particle radiotherapy

Indexed keywords

ACTINIUM 225; APTAMER; LIPOSOME; MONOCLONAL ANTIBODY J591; PROSTATE SPECIFIC MEMBRANE ANTIGEN; ACTINIUM; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; LIGAND; MACROGOL DERIVATIVE; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; RADIOISOTOPE;

ALPHA RADIATION; ANIMAL CELL; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIVASCULAR RADIOTHERAPY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; ENCAPSULATION; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INCUBATION TIME; ISOTOPE LABELING; LD 50; MALE; MEMBRANE VESICLE; MONOLAYER CULTURE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; RADIOACTIVITY; RADIOISOTOPE THERAPY; ANIMAL; ANTI-PSMA LIPOSOMES; ANTIVASCULAR Α-PARTICLE RADIOTHERAPY; CHEMISTRY; FLUORESCENCE MICROSCOPY; LIPOSOMAL 225AC; PROSTATE TUMOR; PROTEIN BINDING; RAT; SCINTISCANNING; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANTI-PSMA LIPOSOMES; ANTIVASCULAR Α-PARTICLE RADIOTHERAPY; LIPOSOMAL 225AC;

ACTINIUM; ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, SURFACE; CELL LINE, TUMOR; GLUTAMATE CARBOXYPEPTIDASE II; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIGANDS; LIPOSOMES; MALE; MICROSCOPY, FLUORESCENCE; POLYETHYLENE GLYCOLS; PROSTATIC NEOPLASMS; PROTEIN BINDING; RADIOISOTOPES; RATS;

EID: 84894778193     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.125476     Document Type: Article

References (38)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82: 4-6.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285: 1182-1186.
3. Burrows FJ, Thorpe PE. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA. 1993;90: 8996-9000.
4. Thorpe PE, Burrows FJ. Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res Treat. 1995;36: 237-251.
5. Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-Associated neovasculature. Cancer Res. 1999;59: 3192-3198.
6. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997;57: 3629-3634.
7. Liu H, Rajasekaran A, Moy P, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 1998;58: 4055-4060.
8. Milowsky MI, Nanus DM, Kostakoglu L, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody j591 in advanced solid tumors. J Clin Oncol. 2007;25: 540-547.
9. Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Research. 2002;62: 4029-4033.
10. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-Aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci. 2006;103: 6315-6320.
11. Humm JL. A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. Int J Radiat Oncol Biol Phys. 1987;13: 1767-1773.
12. Humm JL, Chin LM. A model of cell inactivation by alpha-particle internal emitters. Radiat Res. 1993;134: 143-150.
13. Macklis RM, Kinsey BM, Kassis AI, et al. Radioimmunotherapy with alphaparticle-emitting immunoconjugates. Science. 1988;240: 1024-1026.
14. Sgouros G, Roeske JC, McDevitt MR, et al. MIRD pamphlet No. 22 (abridged): radiobiology and dosimetry of a-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51: 311-328.
15. Miederer M, Scheinberg D, McDevitt M. Realizing the potential of the actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev. 2008;60: 1371-1382.
16. Sofou S, Thomas JL, Lin H-Y, McDevitt MR, Scheinberg DA, Sgouros G. Engineered liposomes for potential a-particle therapy of metastatic cancer. J Nucl Med. 2004;45: 253-260.
17. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43: 693-713.
18. Chang M-Y, Seideman J, Sofou S. Enhanced loading efficiency and retention of 225ac in rigid liposomes for potential targeted therapy of micrometastases. Bioconjug Chem. 2008;19: 1274-1282.
19. Liu C, Huang H, Donate F, et al. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res. 2002;62: 5470-5475.
20. Liu T, Jabbes J, Nedrow-Byers JR, Wu LY, Bryan JN, Berkman CE. Detection of prostate-specific membrane antigen on HUVECs in response to breast tumorconditioned medium. Int J Oncol. 2011;38: 1349-1355.
21. McDevitt MR, Ma D, Simon J, Frank RK, Kiefer GE, Scheinberg DA. Design and synthesis of actinium-225 radioimmunopharmaceuticals. Appl Radiat Isot. 2002;57: 841-847.
22. Allen TM, Brandeis E, Hansen CB, Kao GY, Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta. 1995;1237: 99-108.
23. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 2000;60: 6095-6100.
24. Palm S, Humm JL, Rundqvist R, Jacobsson L. Microdosimetry of astatine-211 single-cell irradiation: role of daughter polonium-211 diffusion. Med Phys. 2004; 31: 218-225.
25. McQuarrie SA, Mercer JR, Syme A, Suresh MR, Miller GG. Preliminary results of nanopharmaceuticals used in the radiotherapy of ovarian cancer. J Pharm Sci. 2005;7: 29-34.
26. Escorcia FE, Henke E, McDevitt MR, et al. Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res. 2010;70: 9277-9286.
27. Sofou S. Surface-Active liposomes for targeted cancer therapy. Nanomedicine (Lond). 2007;2: 711-724.
28. Leveque D, Wisniewski S, Jehl FO. Pharmacokinetics of therapeutic monoclonal antibodies used in oncology. Anticancer Res. 2005;25: 2327-2343.
29. 177Lu? J Nucl Med. 2005;46: 634-641.
30. Pommé S, Marouli M, Suliman G, et al. Measurement of the 225Ac half-life. Appl Radiat Isot. 2012;70: 2608-2614.
31. Noguchi Y, Wu J, Duncan R, et al. Early phase tumor accumulation of macromolecules: a great difference between the tumor vs. normal tissue in their clearance rate. Jpn J Cancer Res. 1998;89: 307-314.
32. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994;54: 3352-3356.
33. Moghimi S. Mechanisms of splenic clearance of blood cells and particles: towards development of new splenotropic agents. Adv Drug Deliv Rev. 1995; 17: 103-115.
34. Borley N, ed. Spleen. London, U.K.: Elsevier; 2005.
35. Heniford BT, Park A, Walsh R, et al. Laparoscopic splenectomy in patients with normal-sized spleens versus splenomegaly: does size matter. Am Surg. 2001;67: 854-857.
36. Takemori N, Hirai K, Onodera R, Kimura S, Katagiri M. Durable remission after splenectomy for Waldenstrom's macroglobulinemia with massive splenomegaly in leukemic phase. Leuk Lymphoma. 1997;26: 387-393.
37. Nikula TK, McDevitt MR, Finn RD, et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med. 1999;40: 166-176.
38. Chouin N, Bernardeau K, Davodeau F, et al. Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. I. Presentation and validation of a microdosimetric model. Radiat Res. 2009;171: 657-663.